CONNECT WITH US
HealthTech

HealthTech

CVS white paper aims to pressure drugmakers to lower GLP-1 prices

Healthcare Dive logo

Published on

Add as a preferred source on Google
CVS white paper aims to pressure drugmakers to lower GLP-1 prices

GLP-1s would save employers money in the long term if they were priced at $350 a month or less, the pharmacy juggernaut found.

LAS VEGAS — GLP-1s for weight loss, diabetes and other conditions can save employers and other payers money — if they’re priced at $350 per month or less, according to a new analysis by CVS Health.

The white paper, released Sunday during the HLTH conference in Las Vegas, found that GLP-1s are associated with better health outcomes, fewer hospitalizations and lower medical spending. But at their current sky-high prices, pharmacy spending on GLP-1s swamps any medical savings for plan sponsors, CVS found. Per the Employee Benefit Research Institute, employers typically pay between $617 and $766 a month for GLP-1s.

The goal of the white paper is to pressure drugmakers like Eli Lilly and Novo Nordisk to lower the cost of the popular medications, according to Dr. Amy Compton-Phillips, CVS’ chief medical officer.

“Employers are having to make these Solomon-like decisions. Like, ‘It seems these are good drugs, but if I pay for them, I can’t afford coverage for my employees,’ right? It’s impossible,” Compton-Phillips said in an interview on the sidelines of HLTH.

GLP-1s have been a golden goose for Lilly and Novo, which capture nearly the entire GLP-1 market through products like Zepbound, Mounjaro, Wegovy and Ozempic.

The global market for GLP-1s is expected to reach $190 billion by 2035, $40 billion more than previously estimated, as the market for weight loss drugs rapidly expands, according to Morgan Stanley.


Source link

Disclaimer

We strive to uphold the highest ethical standards in all of our reporting and coverage. We TheMorningPulse.fyi want to be transparent with our readers about any potential conflicts of interest that may arise in our work. It's possible that some of the investors we feature may have connections to other businesses, including competitors or companies we write about. However, we want to assure our readers that this will not have any impact on the integrity or impartiality of our reporting. We are committed to delivering accurate, unbiased news and information to our audience, and we will continue to uphold our ethics and principles in all of our work. Thank you for your trust and support.